
Counseling Patients With Brain Metastases in RCC
Terence W. Friedlander, MD, of UCSF Helen Diller Family Comprehensive Cancer Center tells Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center that most phase 3 trials in advanced renal cell carcinoma (RCC) excluded active brain metastases, leaving a data gap.
Episodes in this series

Terence W. Friedlander, MD, of UCSF Helen Diller Family Comprehensive Cancer Center tells Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center that most phase 3 trials in advanced renal cell carcinoma (RCC) excluded active brain metastases, leaving a data gap. In CheckMate 920, he says, about a third of patients with brain metastases had shrinkage with ipilimumab plus nivolumab, but a quarter had progression in the brain, so he does not treat brain metastases as an automatic indication for dual immunotherapy. Data are limited for cabozantinib, and the CLEAR trial of lenvatinib excluded these patients. Symptoms, edema, hemorrhage, or mass effect call for early neurosurgery and radiation oncology input and steroids, and he addresses central nervous system disease first before weighing disease elsewhere, often with immunotherapy plus a tyrosine kinase inhibitor. For treated, limited brain disease, he and Dr Plimack say their tumor boards debate whether systemic therapy is needed at all.
Related to this article








